It’s
common knowledge that law tends to trail technology and social movements,
sometimes by years, sometimes by decades. The process of getting new ideas
codified in clear and workable legislation can be a long and arduous path,
often spotted with periods of contradictory or inconsistently enforced
regulations. Nevertheless, after a certain amount of trial and error, the dust
eventually settles, issues get clarified, and real changes can take effect.
The
mounting pressure to allow the use of cannabinoids for the palliative treatment
of patients with cancer and other diseases has begun to open the door to a
multi-billion dollar market in the U.S., also potentially generating billions
in tax revenue. The amount of money involved in all this has led to contentious
ballot measures at state and city levels throughout the country, with
increasing degrees of legalization expected to be pushed through for years to
come.
Although
the legalization of recreational marijuana is in the sites of various activist
groups, by far the most wide-spread support continues to focus on cannabinoids
for medical use. And it’s not just for cancer. A number of painful and
debilitating diseases are now considered targets for the use of medical
cannabis. For example, according to a recent report in silive.com
(http://dtn.fm/8HtB), both U.S. senators from New York have called on the
Department of Justice to allow for the speed up of the state’s new medical
marijuana dispensing program for children experiencing epilepsy and other
seizure disorders.
However,
in spite of the fact that marijuana has already established itself as a major
industry in California and elsewhere, it’s an industry that is still largely
unorganized and fragmented. As a result, there remain huge quality and
information gaps, a mounting problem for new patients who are used to dealing
with the medical establishment. The lack of modern controlled research and
product development has hampered progress. Still, for some companies, this has
represented a unique opportunity.
Cannabics
Pharmaceuticals Inc. has been working to introduce much needed technology and
control to the development of cannabinoid based products. Interestingly, the
company itself does not manufacture, distribute, or dispense any controlled
substances. Rather it develops proprietary technologies that are then licensed
for use by certified and governmentally approved manufacturers and
distributors. Their goal is the scientific determination of efficacy for
various cannabis strains as therapies for specific indications, along with the
best administration routes for active cannabinoids, something severely lacking
in the U.S. medical cannabis industry since regulation essentially halted it
nearly a century ago.
The
company has already formulated carefully-researched Cannabics SR Capsules
targeting cancer patients, and has achieved Good Manufacturing Practices (GMP)
capabilities in preparation for its first clinical study of the capsules.
Adhering to these practices ranks the company’s products among a very limited
number of medical cannabis products available in the U.S. market that are
manufactured according to GMP standards.
For
more information, visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment